Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene

JAMA Internal Medicine

Volumn 175, Issue 6, 2015, Pages 978-987

  Larochelle, Marc R ^a,b   Zhang, Fang ^a   Ross Degnan, Dennis ^a   Wharam, J Frank ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTROPROPOXYPHENE; DIAMORPHINE; OPIATE; OXYCODONE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; DRUG ABUSE; DRUG INTOXICATION; DRUG OVERDOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE; HUMAN; INSURANCE; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; PATIENT SELECTION; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; ADOLESCENT; CLINICAL PRACTICE; DRUG RECALL; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; DEXTROPROPOXYPHENE; DRUG OVERDOSE; FEMALE; HUMANS; MALE; OXYCODONE; PHYSICIAN'S PRACTICE PATTERNS; SAFETY-BASED DRUG WITHDRAWALS; UNITED STATES; YOUNG ADULT;

EID: 84930712812     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.0914     Document Type: Article

References (48)

1. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659.
2. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492.
3. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med. 2006;31(6):506-511.
4. Goodnough A, Zezima K. Drug is harder to abuse, but users persevere. New York Times. June 15, 2011 2011;health:A21. http://www.nytimes.com/2011/06/16/health/16oxy.html. Accessed February 11, 2014.
5. Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009. PLoS One. 2013;8(2):e54496.doi:10.1371/journal.pone.0054496.
6. Pergolizzi JV Jr, Lequang JA. Abuse-deterrent formulations of opioid analgesics. Pain Pract. 2013;14(3):204-206.
7. Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc. 2012;87(7):683-694.
8. Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005;6(10):662-672.
9. Miller RR, Feingold A, Paxinos J. Propoxyphene hydrochloride: a critical review. JAMA. 1970;213(6):996-1006.
10. Claghorn JL, Schoolar JC. Propoxyphene hydrochloride, a drug of abuse. JAMA. 1966;196(12):1089-1091.
11. Soumerai SB, Avorn J, Gortmaker S, Hawley S. Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene. Am J Public Health. 1987;77(12):1518-1523.
12. Center for Substance Abuse Research. Nearly 14% of US residents report lifetime nonmedical use of prescription pain relievers; hydrocodone, codeine/propoxyphene, and oxycodone products most commonly used. http://www.cesar.umd.edu/cesar/cesarfax/vol20/20-44.pdf. Published November 21, 2011. Accessed December 3, 2014.
13. Dal Pan GJ. Updated epidemiological review of propoxyphene safety-FDA. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM234383.pdf. Published November 19, 2010. Accessed December 4, 2014.
14. Propoxyphene FDA. Withdrawal - risk of cardiac toxicity. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm234389.htm. Published November 19, 2010. Accessed December 3, 2014.
15. Hwang CS, Chang HY, Alexander GC. Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiol Drug Saf. 2015;24(2):197-204.
16. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22(12):1274-1282.
17. Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23(12):1238-1246.
18. Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R. Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Curr Med Res Opin. 2014;30(8):1589-1598.
19. McNaughton EC, Coplan PM, Black RA, Weber SE, Chilcoat HD, Butler SF. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse. J Med Internet Res. 2014;16(5):e119.
20. Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.J Pain. 2013;14(10):1122-1130.
21. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351-358.
22. Cassidy TA, Dasmahapatra P, Black RA, Wieman MS, Butler SF. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2013.
23. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187-189.
24. Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521-527.
25. Injury Surveillance Workgroup 7. Consensus Recommendations for National and State Poisoning Surveillance. Atlanta, GA: Safe States Alliance; April 2012.
26. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
27. McCarty D, Janoff S, Coplan P, et al. Detection of opioid overdoses and poisonings in electronic medical records as compared to medical chart reviews. Presentation to FDA, May 20, 2014. http://www.fda.gov/downloads/Drugs/NewsEvents/UCM398787.pdf. Accessed December 4, 2014.
28. Census 2000 Summary File 1; United States. Washington, DC: US Census Bureau; 2001.
29. Fiscella K, Fremont AM. Use of geocoding and surname analysis to estimate race and ethnicity. Health Serv Res. 2006;41(4, pt 1):1482-1500.
30. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV. Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures-the public health disparities geocoding project. Am J Public Health. 2003;93(10):1655-1671.
31. US Dept of Commerce, Economics, and Statistics Administration, Bureau of the Census. Geographic Areas Reference Manual. Washington, DC: US Bureau of the Census; 1994.
32. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
33. Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol. 2009;62(2):143-148.
34. Cohen RA, Martinez ME. Health insurance coverage: early release of estimates from the National Health Interview Survey, January-March 2013. http://www.cdc.gov/nchs/data/nhis/earlyrelease/insur201309.pdf. Published September 2013. Accessed December 4, 2014.
35. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-2620.
36. Centers for Disease Control and Prevention (CDC). Overdose deaths involving prescription opioids among Medicaid enrollees-Washington, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009;58(42):1171-1175.
37. Office of Applied Studies, Substance Abuse and Mental Health Services Administration. Nonmedical users of pain relievers: characteristics of recent initiates. The NSDUH Report. 2006(22). http://www.oas.samhsa.gov/2k6/pain/pain.htm. Accessed December 1, 2014.
38. Pollini RA, Banta-Green CJ, Cuevas-Mota J, Metzner M, Teshale E, Garfein RS. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abuse Rehabil. 2011;2(1):173-180.
39. Lankenau SE, Teti M, Silva K, Jackson Bloom J, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23(1):37-44.
40. Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014;139:9-17.
41. Jones CM, Paulozzi LJ, Mack KA. Sources of prescription opioid pain relievers by frequency of past-year nonmedical use: United States: 2008-2011. JAMA Intern Med. 2014;174(5):802-803.
42. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Interference. Belmont, CA: Houghton Mifflin; 2001:171-206.
43. Bohnert AS, Ilgen MA, Galea S, McCarthy JF, Blow FC. Accidental poisoning mortality among patients in the Department of Veterans Affairs Health System. Med Care. 2011;49(4):393-396.
44. Valencia MJ. Mass. limits use of the potent painkiller Zohydro. Boston Globe. April 23, 2014 Metro. http://www.bostonglobe.com/metro/2014/04/22/governor-deval-patrick-administration-enacts-new-restrictions-zohydro/GpIZM4OUOgZg7cWEI8XV5N/story.html. Accessed May 6, 2014.
45. Dasgupta N, Creppage K, Austin A, Ringwalt C, Sanford C, Proescholdbell SK. Observed transition from opioid analgesic deaths toward heroin. Drug Alcohol Depend. 2014;145:238-241.
46. Banta-Green C. Heroin trends across Washington State. University of Washington Alcohol and Drug Abuse Institute info brief. http://adai.uw.edu/pubs/InfoBriefs/ADAI-IB-2013-02.pdf. Published June 2013. Accessed February 5, 2014.
47. Maryland Department of Health and Mental Hygiene. Drug and alcohol intoxication deaths in Maryland, 2007-2012. http://bha.dhmh.maryland.gov/OVERDOSE-PREVENTION/Documents/2007-2012%20intox%20report-final.pdf. Published July 2013. Accessed February 5, 2014.
48. Paone D, Tuazon E, Nolan M, O'Brien B. Unintentional drug poisoning (overdose) deaths in New York City, 2000-2012. New York City Dept of Health and Mental Hygeine epidemiological data brief. http://www.nyc.gov/html/om/pdf/2013/edb-unintentional-drug-poisoning-overdose-deaths.pdf. Published September 2013. Accessed February 5, 2014.